))
Mythbusting LCS Eligibility: Biomarker Testing (Part 4)
Manage episode 336657110 series 3378142
المحتوى المقدم من American College of Radiology and National Lung Cancer Roundtable, American College of Radiology, and National Lung Cancer Roundtable. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة American College of Radiology and National Lung Cancer Roundtable, American College of Radiology, and National Lung Cancer Roundtable أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
*This episode was originally part of the ACR Bulletin podcast and was recorded in 2020.
For part four of their discussion, Dr. Debra Dyer, MD, and Dr. Patricia Rivera, MD, discuss the importance of biomarker testing for patients with advanced NSCLC.
As part of National Lung Cancer Awareness Month 2020, Dr. Debra Dyer, Chair of the ACR’s Lung Cancer Screening Steering Committee, had a series of conversations with stakeholders across the healthcare spectrum about myths in lung screening in the limited series “Mythbusting Lung Cancer Screening.”
Dr. Patricia Rivera is a Professor of Medicine in the Division of Pulmonary Diseases and Critical Care Medicine at the University of North Carolina at Chapel Hill. Dr. Rivera currently serve as Co-Director of the Multidisciplinary Thoracic Oncology Program and Director of the Lung Cancer Screening Program at UNC. She serves as Secretary-Treasurer of the American Thoracic Society and will serve as President of ATS in 2023. She is a member of the National Lung Cancer Roundtable and serves as Vice-Chair of the Lung Cancer in Women and the Biomarker Task Forces.
Additional information on this topic, as well as the resources mentioned during the episode, can be found at https://www.acr.org/Clinical-Resources/Lung-Cancer-Screening-Resources.
40 حلقات
مشاركة
